QI
ENTA icon

QS Investors’s Enanta Pharmaceuticals ENTA Stock Holding History

QS Investors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$463K Hold
10,500
– – 0.01% 769
2021
Q1 		$518K Sell
10,500
-200
-2% -$9.98K 0.01% 787
2020
Q4 		$450K Hold
10,700
– – 0.01% 834
2020
Q3 		$490K Sell
10,700
-35,660
-77% -$1.73M 0.01% 701
2020
Q2 		$2.33M Buy
46,360
+2,200
+5% +$114K 0.03% 427
2020
Q1 		$2.27M Hold
44,160
– – 0.04% 374
2019
Q4 		$2.74M Sell
44,160
-680
-2% -$42.2K 0.03% 481
2019
Q3 		$2.69M Hold
44,840
– – 0.03% 459
2019
Q2 		$3.78M Sell
44,840
-781
-2% -$70.3K 0.04% 355
2019
Q1 		$4.36M Sell
45,621
-25,493
-36% -$2.29M 0.05% 312
2018
Q4 		$5.04M Hold
71,114
– – 0.06% 214
2018
Q3 		$6.08M Buy
71,114
+100
+0.1% +$10K 0.06% 223
2018
Q2 		$8.23M Sell
71,014
-300
-0.4% -$29.9K 0.08% 164
2018
Q1 		$5.77M Sell
71,314
-4,390
-6% -$338K 0.06% 214
2017
Q4 		$4.44M Sell
75,704
-705
-0.9% -$35.3K 0.04% 334
2017
Q3 		$3.58M Sell
76,409
-1,383
-2% -$55.6K 0.03% 415
2017
Q2 		$2.8M Sell
77,792
-549
-0.7% -$17.6K 0.02% 491
2017
Q1 		$2.41M Hold
78,341
– – 0.02% 541
2016
Q4 		$2.62M Sell
78,341
-12,675
-14% -$363K 0.02% 542
2016
Q3 		$2.42M Hold
91,016
– – 0.02% 603
2016
Q2 		$2.01M Sell
91,016
-4,900
-5% -$128K 0.02% 632
2016
Q1 		$2.82M Buy
95,916
+4,900
+5% +$136K 0.03% 559
2015
Q4 		$3M Buy
91,016
+13,503
+17% +$440K 0.03% 552
2015
Q3 		$2.8M Hold
77,513
– – 0.03% 531
2015
Q2 		$3.49M Hold
77,513
– – 0.04% 478
2015
Q1 		$2.37M Hold
77,513
– – 0.03% 560
2014
Q4 		$3.94M Buy
+77,513
New +$3.47M 0.05% 421

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

QS Investors's ENTA Position: Q2 2021 in Review

QS Investors held its Enanta Pharmaceuticals (ENTA) position steady in Q2 2021 at 10,500 shares worth $463K. The position accounts for 0.01% of the portfolio, ranked #769.

QS Investors first reported a position in ENTA in Q4 2014 and has held it in 27 quarters since. The position peaked at $8.23M in Q2 2018. 152 funds tracked by Wall St. Rank hold ENTA as of Q2 2021.

  • QS Investors held 10,500 shares of Enanta Pharmaceuticals worth $463K as of Q2 2021.
  • QS Investors left its Enanta Pharmaceuticals share count unchanged in Q2 2021.
  • Enanta Pharmaceuticals made up 0.01% of QS Investors's portfolio in Q2 2021, its #769 holding.
  • QS Investors first reported a position in Enanta Pharmaceuticals in Q4 2014 and has held it in 27 quarters since.
  • QS Investors's Enanta Pharmaceuticals position peaked at $8.23M in Q2 2018.
  • 152 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.